Novartis AG is drip-feeding data from its APPLAUSE-IgAN trial. The study, assessing the oral complement factor B inhibitor Fabhalta (iptacopan) in IgA nephropathy (IgAN), was toplined a success in October. Now the company has revealed the finding on one of the two co-primary endpoints, saying that Fabhalta-treated patients achieved a statistically significant (p<0.0001) reduction in proteinuria.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
